学術論文　2018

  1. Maekawa, S.; Sato, M.; Kuratomi, N.; Inoue, T.; Suzuki, Y.; Tatsumi, A.; Miura, M.; Matsuda, S.; Muraoka, M.; Nakakuki, N.; et al. Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C. J Gastroenterol 2018, 53, 780–786, doi:10.1007/s00535-017-1405-3.
  2. Kobayashi, S.; Yamaguchi, T.; Maekawa, S.; Takano, S.; Kuno, T.; Tanaka, K.; Tsukui, Y.; Iwamoto, F.; Yoshida, T.; Asakawa, Y.; et al. Target sequencing of cancer-related genes in early esophageal squamous neoplasia resected by endoscopic resection in Japanese patients. Oncotarget 2018, 9, 36793–36803, doi:10.18632/oncotarget.26397.
  3. Yasui, Y.; Kurosaki, M.; Komiyama, Y.; Takada, H.; Tamaki, N.; Watakabe, K.; Okada, M.; Wang, W.; Shimizu, T.; Kubota, Y.; et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. Hepatol. Res. 2018, 48, 1131–1139, doi:10.1111/hepr.13233.
  4. Iwamoto, F.; Matsuoka, K.; Motobayashi, M.; Takenaka, K.; Kuno, T.; Tanaka, K.; Tsukui, Y.; Kobayashi, S.; Yoshida, T.; Fujii, T.; et al. Prediction of disease activity of Crohn’s disease through fecal calprotectin evaluated by balloon-assisted endoscopy. J. Gastroenterol. Hepatol. 2018, 33, 1984–1989, doi:10.1111/jgh.14310.
  5. Maekawa, S.; Enomoto, N. The “real-world” efficacy and safety of DAAs for the treatment of HCV patients throughout Japan. J. Gastroenterol. 2018, 53, 1168–1169.
  6. Asahina, Y.; Itoh, Y.; Ueno, Y.; Matsuzaki, Y.; Takikawa, Y.; Yatsuhashi, H.; Genda, T.; Ikeda, F.; Matsuda, T.; Dvory-Sobol, H.; et al. Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection. Liver Int.  Off. J. Int. Assoc.  Study Liver 2018, 38, 1552–1561, doi:10.1111/liv.13685.
  7. Takada, H.; Kurosaki, M.; Nakanishi, H.; Takahashi, Y.; Itakura, J.; Tsuchiya, K.; Yasui, Y.; Tamaki, N.; Takaura, K.; Komiyama, Y.; et al. Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma. PLoS One 2018, 13, e0198812, doi:10.1371/journal.pone.0198812.
  8. Yasui, Y.; Tsuchiya, K.; Kurosaki, M.; Takeguchi, T.; Takeguchi, Y.; Okada, M.; Wang, W.; Kubota, Y.; Goto, T.; Komiyama, Y.; et al. Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. Hepatol. Res. 2018, 48, 442–450, doi:10.1111/hepr.13048.
  9. Kumada, H.; Watanabe, T.; Suzuki, F.; Ikeda, K.; Sato, K.; Toyoda, H.; Atsukawa, M.; Ido, A.; Takaki, A.; Enomoto, N.; et al. Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J. Gastroenterol. 2018, 53, 689, doi:10.1007/s00535-017-1409-z.
  10. Ichikawa, S.; Motosugi, U.; Hernando, D.; Morisaka, H.; Enomoto, N.; Matsuda, M.; Onishi, H. Histological Grading of Hepatocellular Carcinomas with Intravoxel Incoherent Motion Diffusion-weighted Imaging: Inconsistent Results Depending on the Fitting Method. Magn. Reson. Med. Sci.  MRMS  an Off. J. Japan Soc.  Magn. Reson. Med. 2018, 17, 168–173, doi:10.2463/mrms.mp.2017-0047.
  11. Kumada, H.; Watanabe, T.; Suzuki, F.; Ikeda, K.; Sato, K.; Toyoda, H.; Atsukawa, M.; Ido, A.; Takaki, A.; Enomoto, N.; et al. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J. Gastroenterol. 2018, 53, 566–575, doi:10.1007/s00535-017-1396-0.
  12. Murata, K.; Asano, M.; Matsumoto, A.; Sugiyama, M.; Nishida, N.; Tanaka, E.; Inoue, T.; Sakamoto, M.; Enomoto, N.; Shirasaki, T.; et al. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut 2018, 67, 362–371, doi:10.1136/gutjnl-2016-312653.
  13. Miura, M.; Ohtaka, M.; Hanawa, M.; Kitahashi, A.; Hirose, Y.; Takaso, K.; Yoda, Y.; Takayama, I.; Yamagata, Z.; Enomoto, N. [Infection status of Helicobacter pylori with antibody values of 3.0U/mL or more and less than 10.0U/mL in the LZ test “Eiken” H. pylori antibody]. Nihon Shokakibyo Gakkai Zasshi 2018, 115, 721–731, doi:10.11405/nisshoshi.115.721.
  14. Imagawa, N.; Fukasawa, M.; Takahashi, E.; Shindo, H.; Takano, S.; Sato, T.; Kawaida, H.; Fujii, H.; Nakazawa, T.; Enomoto, N. [Case of main duct-intraductal papillary mucinous carcinoma (pancreatobiliary type) causing 4-mm dilatation of the pancreatic duct]. Nihon Shokakibyo Gakkai Zasshi 2018, 115, 305–312, doi:10.11405/nisshoshi.115.305.